New leadership roles to drive operational readiness and regional growth for the company in Japan
Today, we announced significant leadership updates to coincide with the groundbreaking of its new state-of-the-art Yokohama site in Japan.
Jun Takami, previously General Manager of the Chiba site, will now lead operational readiness for the Yokohama site while continuing his leadership of AGC Biologics' Japan Region operations. He will join the Yokohama project team to establish organizational readiness for CDMO services, lead customer outreach as Yokohama Site General Manager, and develop future strategies for the site and the Japan Region. The overall construction project will be managed by Ryo Kanno.
“Jun has played a pivotal role in advancing AGC Biologics’ capabilities in Japan,” said Kasper Møller, PhD, Chief Technical Officer of AGC Biologics. “With over 15 years of leadership experience in the pharmaceutical industry and seven years at AGC, his expertise has been instrumental in introducing mammalian capacity at the Chiba site and executing both microbial and mammalian projects. I am confident he will bring the same vision and excellence to our Yokohama site.”
To ensure seamless leadership at the Chiba site, AGC Biologics has appointed Susumu Zenin as the new General Manager, where he will oversee continued growth and innovation at the facility. Zenin has been with the company since 2015, serving in various leadership roles, including Head of Microbial Manufacturing and Head of Process Development.
“Susumu’s strong leadership and technical expertise have delivered exceptional results for the Chiba site, from achieving record batch success rates to ensuring stable operations and effective problem-solving,” said Møller. “He is the ideal leader to continue driving the success of our Chiba operations.”
With these strategic appointments, AGC Biologics aims to enhance collaboration and synergies between the Chiba and Yokohama sites to meet the growing demand for lifesaving biopharmaceutical products.
“I am honored to take on this critical role for the Yokohama site,” said Takami. “We intend to provide cutting-edge CDMO services to customers worldwide, and I am dedicated to ensuring seamless operations and outstanding performance at this new facility.”
“I look forward to leading the Chiba site and building on its strong foundation,” said Zenin. “Together, our sites will work closely to support AGC Biologics’ objective of delivering innovative solutions to patients around the globe.”
To learn more about AGC Biologics and its global CDMO services, visit www.agcbio.com.
